Table 6.

Number of Anti-VEGF Injections after the First Year Categorized According to Number of Anti-VEGF Injections in the First Year

Number of Anti-VEGF in the First 12 Mos	Cases (No./%)		Average Number of Anti-VEGF Injections within the Specified Period (±SD)
			Accumulative				By the Year
			0–24 mos	0–36 mos	0–48 mos	0–60 mos	13–24 mos	25–36 mos	37–48 mos	49–60 mos
1	35 108	18.7	1.26 ± 0.85	1.55 ± 1.62	1.91 ± 2.49	2.41 ± 3.60	0.26 ± 0.85	0.29 ± 0.99	0.33 ± 1.09	0.38 ± 1.22
2	25 473	13.6	2.52 ± 1.14	3.05 ± 2.14	3.62 ± 3.27	4.34 ± 4.59	0.52 ± 1.14	0.52 ± 1.28	0.54 ± 1.39	0.59 ± 1.55
3	50 136	26.8	3.65 ± 1.31	4.33 ± 2.47	5.02 ± 3.66	5.76 ± 4.93	0.65 ± 1.31	0.68 ± 1.50	0.69 ± 1.58	0.73 ± 1.68
4	23 073	12.3	5.41 ± 1.76	6.67 ± 3.25	7.88 ± 4.77	9.14 ± 6.37	1.41 ± 1.76	1.24 ± 1.87	1.16 ± 1.95	1.19 ± 2.11
5	16 306	8.7	7.09 ± 2.08	8.87 ± 3.88	10.56 ± 5.66	12.25 ± 7.49	2.09 ± 2.08	1.77 ± 2.21	1.63 ± 2.29	1.60 ± 2.41
6	14 665	7.8	8.53 ± 2.27	10.66 ± 4.27	12.58 ± 6.30	14.48 ± 8.39	2.53 ± 2.27	2.12 ± 2.46	1.95 ± 2.55	1.87 ± 2.63
7	10 693	5.7	10.5 ± 2.47	13.4 ± 4.83	16.00 ± 7.16	18.82 ± 9.63	3.50 ± 2.47	2.89 ± 2.80	2.65 ± 2.85	2.57 ± 3.00
8	5730	3.1	12.3 ± 2.71	15.92 ± 5.31	18.98 ± 7.89	21.87 ± 10.45	4.31 ± 2.71	3.57 ± 3.07	3.10 ± 3.19	2.99 ± 3.29
9	2983	1.6	14.0 ± 3.01	18.21 ± 3.04	21.35 ± 7.81	24.38 ± 11.85	5.01 ± 3.01	4.14 ± 3.57	3.47 ± 3.47	3.31 ± 3.65
10	1655	0.9	15.86 ± 3.25	20.41 ± 6.26	24.64 ± 9.44	28.47 ± 12.45	5.86 ± 3.25	4.71 ± 3.63	4.27 ± 3.89	4.00 ± 3.78
11	976	0.5	17.84 ± 3.51	23.29 ± 6.82	27.48 ± 10.05	31.72 ± 13.92	6.84 ± 3.51	5.53 ± 3.90	4.70 ± 4.15	4.22 ± 4.29
12	621	0.3	19.6 ± 3.80	25.22 ± 7.83	29.79 ± 11.92	33.68 ± 14.28	7.58 ± 3.80	5.72 ± 4.61	4.82 ± 4.70	4.09 ± 4.19

SD = standard deviation; VEGF = vascular endothelial growth factor.

The first 12 months refer to the 12 months from each initial treatment.

Injection numbers are presented as mean ± standard deviation.